ArriVent BioPharma, Inc. AVBP
13.52 USD +0.01 (+0.11%)
Nov 12, 2026, 12:02 PM EST
12.89 Day range 13.60
11.36 52-week range 35.83
- YTD
- -32.80%
- 1 year
- -33.07%
News
benzinga.com Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24 Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.
benzinga.com ArriVent BioPharma Q3 EPS $(0.81) Beats $(1.05) Estimate, Sales $5.000M ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.05) by 22.86 percent. This is a 2.41 percent increase over losses of…
globenewswire.com ArriVent BioPharma Reports Third Quarter 2026 Financial Results Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed…
benzinga.com Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30 Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
benzinga.com ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced…
benzinga.com B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29 B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.- benzinga.com BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.
- benzinga.com ArriVent BioPharma Doses First Patient In Phase 1 Trial Of Dual-Target ADC ARR-002 For Ovarian And Endometrial Cancer ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced…
- benzinga.com Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.
benzinga.com HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27 HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.
benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.- benzinga.com Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18 Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.- benzinga.com Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18 Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
- benzinga.com BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29 BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.
benzinga.com ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH)…
benzinga.com Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
benzinga.com Dow Jumps 200 Points; US Trade Deficit Widens In August U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. Utilities gained; energy and oil fell.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.- benzinga.com HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47 HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.
benzinga.com Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.- benzinga.com BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price Target BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $42 price target.
- benzinga.com ArriVent BioPharma Q2 EPS $(1.05) Misses $(0.99) Estimate ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 16.67 percent decrease over losses of…
- benzinga.com Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45 Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $43 to $45.
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $43 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $43.
benzinga.com ArriVent Biopharma Launches $250M At-The-Market Common Stock Offering Through Jefferies $250,000,000Common StockWe have entered into an Open Market Sale AgreementSM (the sales agreement) with Jefferies LLC (Jefferies), as our sales agent, relating to the shares of our common stock…- benzinga.com ArriVent BioPharma Q1 EPS $(0.96) Misses $(0.86) Estimate ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.86) by 11.63 percent. This is a 49.47 percent increase over losses…
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $45 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $33 to $45.
benzinga.com Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and sales estimates. Other stocks also decline.- benzinga.com B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45 B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $37 to $45.
- benzinga.com ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor…
- benzinga.com BTIG Assumes ArriVent BioPharma at Buy, Announces Price Target of $42 BTIG analyst Jeet Mukherjee assumes ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $42.
- benzinga.com Oppenheimer Reiterates Outperform on ArriVent BioPharma, Raises Price Target to $50 Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and raises the price target from $44 to $50.
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $33 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $31 to $33.
benzinga.com HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $44 HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $42 to $44.- benzinga.com ArriVent BioPharma Q4 EPS $(0.78) Beats $(0.83) Estimate ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.83) by 5.68 percent. This is a 27.87 percent decrease over losses of…
- benzinga.com Cantor Fitzgerald Initiates Coverage On ArriVent BioPharma with Overweight Rating Cantor Fitzgerald analyst Li Watsek initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Overweight rating.
- benzinga.com ArriVent Doses First Patient In Phase 3 ALPACCA Trial Of Firmonertinib For The Treatment Of EGFR-Mutant NSCLC Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to…
- benzinga.com BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45 BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.
- benzinga.com Truist Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $43 Truist Securities analyst Asthika Goonewardene initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $43.
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $31 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $33 to $31.
- benzinga.com ArriVent BioPharma Q3 EPS $(0.83) Misses $(0.81) Estimate ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.81) by 2.85 percent. This is a 36.07 percent decrease over losses of…
- benzinga.com ArriVent BioPharma Presents Final Proof-Of-Concept Data From Randomized Global Phase 1b FURTHER Trial For First-Line Firmonertinib Monotherapy In Patients With NSCLC Harboring EGFR PACC Mutations At IASCLC 2025 16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and…
- benzinga.com HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $42 HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $40 to $42.
- benzinga.com Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $33 Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $33.